NO20031626D0 - Pyridonderivater for behandling av atherosklerose - Google Patents

Pyridonderivater for behandling av atherosklerose

Info

Publication number
NO20031626D0
NO20031626D0 NO20031626A NO20031626A NO20031626D0 NO 20031626 D0 NO20031626 D0 NO 20031626D0 NO 20031626 A NO20031626 A NO 20031626A NO 20031626 A NO20031626 A NO 20031626A NO 20031626 D0 NO20031626 D0 NO 20031626D0
Authority
NO
Norway
Prior art keywords
atherosclerosis
treatment
pyridone derivatives
pyridone
derivatives
Prior art date
Application number
NO20031626A
Other languages
English (en)
Other versions
NO20031626L (no
NO325107B1 (no
Inventor
Deirdre Mary Bernadette Hickey
Robert John Ife
Colin Andrew Leach
John Liddle
Ivan Leo Pinto
Stephen Allan Smith
Steven James Stanway
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO20031626D0 publication Critical patent/NO20031626D0/no
Publication of NO20031626L publication Critical patent/NO20031626L/no
Publication of NO325107B1 publication Critical patent/NO325107B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Structural Engineering (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20031626A 2000-10-10 2003-04-09 Pyridonderivater, fremgangsmate for fremstilling av disse, farmasoytiske preparater omfattende slike, slike forbindelser til anvendelse i terapi og for fremstilling av medikamenter for behandling av atherosklerose NO325107B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0024808.8A GB0024808D0 (en) 2000-10-10 2000-10-10 Novel compounds
PCT/EP2001/011610 WO2002030904A1 (en) 2000-10-10 2001-10-05 Pyridinone derivatives for treatment of atherosclerosis

Publications (3)

Publication Number Publication Date
NO20031626D0 true NO20031626D0 (no) 2003-04-09
NO20031626L NO20031626L (no) 2003-06-04
NO325107B1 NO325107B1 (no) 2008-02-04

Family

ID=9901006

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031626A NO325107B1 (no) 2000-10-10 2003-04-09 Pyridonderivater, fremgangsmate for fremstilling av disse, farmasoytiske preparater omfattende slike, slike forbindelser til anvendelse i terapi og for fremstilling av medikamenter for behandling av atherosklerose

Country Status (29)

Country Link
US (2) US20040063753A1 (no)
EP (2) EP2258688B1 (no)
JP (1) JP4212354B2 (no)
KR (1) KR100824134B1 (no)
CN (2) CN1951917B (no)
AR (1) AR035349A1 (no)
AT (1) ATE538096T1 (no)
AU (2) AU1052402A (no)
BR (1) BRPI0114576B1 (no)
CA (1) CA2425268C (no)
CY (2) CY1112442T1 (no)
CZ (1) CZ304558B6 (no)
DK (2) DK2258688T3 (no)
ES (2) ES2378059T3 (no)
GB (1) GB0024808D0 (no)
GC (1) GC0000307A (no)
HK (2) HK1144941A1 (no)
HU (1) HU230767B1 (no)
IL (2) IL155278A0 (no)
MX (1) MXPA03003176A (no)
MY (1) MY135766A (no)
NO (1) NO325107B1 (no)
NZ (1) NZ525225A (no)
PL (1) PL207560B1 (no)
PT (2) PT2258688E (no)
SI (2) SI1326841T1 (no)
TW (1) TWI293293B (no)
WO (1) WO2002030904A1 (no)
ZA (1) ZA200302785B (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ520752A (en) * 2000-02-16 2004-03-26 Smithkline Beecham P Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors
GB0119793D0 (en) * 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel compounds
GB0127140D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127139D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0208280D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
GB0208279D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
US7741020B2 (en) 2004-04-16 2010-06-22 Glaxo Group Limited Methods for detecting Lp-PLA2 activity and inhibition of Lp-PLA2 activity
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
US7705005B2 (en) * 2006-10-13 2010-04-27 Glaxo Group Limited Bicyclic heteroaromatic compounds
US20080090852A1 (en) * 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US20080090851A1 (en) * 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
WO2008140449A1 (en) 2007-05-11 2008-11-20 Thomas Jefferson University Methods of treatment and prevention of neurodegenerative diseases and disorders
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
BRPI0810336A2 (pt) 2007-05-11 2019-03-19 The Trustees Of The University Of Pennsylvania "método para tratar e/ou prevenir úlceras de pele em um indivíduo"
US8575348B2 (en) 2009-07-28 2013-11-05 Auspex Pharmaceuticals, Inc Quinolone inhibitors of lipoprotein-associated phospholipase A2
US9512104B2 (en) 2009-07-28 2016-12-06 Auspex Pharmaceuticals, Inc. Quinolone inhibitors of lipoprotein-associated phospholipase A2
WO2011049722A1 (en) * 2009-10-19 2011-04-28 Merck Sharp & Dohme Corp. PYRAZOLO [3,4-b] PYRIDIN-4-ONE KINASE INHIBITORS
JP6053675B2 (ja) 2010-06-18 2016-12-27 ホワイトヘッド・インスティチュート・フォア・バイオメディカル・リサーチ 抗ウイルス化合物のためのターゲットとしてのｐｌａ２ｇ１６
EP2649050A4 (en) * 2010-12-06 2014-04-23 Glaxo Group Ltd LINKS
ES2559224T3 (es) * 2010-12-06 2016-02-11 Glaxo Group Limited Compuestos de pirimidinona para uso en el tratamiento de enfermedades o condiciones mediadas por Lp-PLA2
EP2651403B1 (en) 2010-12-17 2020-12-02 Glaxo Group Limited Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
WO2013000108A1 (zh) * 2011-06-27 2013-01-03 中国科学院上海药物研究所 唑类杂环化合物、其制备方法、药物组合物和用途
JP2014521625A (ja) 2011-07-27 2014-08-28 グラクソ グループ リミテッド 二環式ピリミドン化合物
JP2014521611A (ja) 2011-07-27 2014-08-28 グラクソ グループ リミテッド Ｌｐ−ＰＬＡ２阻害剤としての２，３−ジヒドロイミダゾ［１，２−ｃ］ピリミジン−５（１Ｈ）−オン化合物の使用
PE20141411A1 (es) * 2011-09-01 2014-10-29 Glaxo Group Ltd Nueva forma de cristal
EP2948452B1 (en) 2013-01-25 2017-08-09 GlaxoSmithKline Intellectual Property Development Limited 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors
CA2899143A1 (en) 2013-01-25 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Bicyclic pyrimidone compounds as inhibitors of lp-pla2
CA2899124A1 (en) 2013-01-25 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Compounds
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
CN104840963B (zh) * 2015-05-26 2018-02-16 河北东康生物科技有限公司 含脂蛋白相关性磷脂酶a2抑制剂的药物组合物及应用
US10464896B2 (en) 2015-06-11 2019-11-05 Basilea Pharmaceutica International AG Efflux-pump inhibitors and therapeutic uses thereof
CN112574221B (zh) * 2019-09-30 2022-03-04 上海纽思克生物科技有限公司 四环嘧啶酮类化合物、其制备方法、其组合物和用途
WO2021089032A1 (zh) 2019-11-09 2021-05-14 上海赛默罗生物科技有限公司 三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途
CN112510260B (zh) * 2020-11-27 2022-11-04 珠海市赛纬电子材料股份有限公司 电解液添加剂、非水电解液和锂离子电池
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5769527A (en) 1986-07-17 1998-06-23 Vari-Lite, Inc. Computer controlled lighting system with distributed control resources
US5585246A (en) 1993-02-17 1996-12-17 Biometric Imaging, Inc. Method for preparing a sample in a scan capillary for immunofluorescent interrogation
JPH08500740A (ja) 1993-06-25 1996-01-30 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー リポタンパク質関連ホスホリパーゼａ▲下２▼、その阻害剤および診断および治療におけるその使用
EP1634953A3 (en) 1993-10-06 2006-06-28 ICOS Corporation Platelet-activating factor acethylhydrolase
GB9421816D0 (en) 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
HUT77089A (hu) 1994-12-22 1998-03-02 Smithkline Beecham Plc. Atherosclerosis kezelésére alkalmas szubsztituált 2-oxo-azetidinek, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
CH690264A5 (fr) 1995-06-30 2000-06-30 Symphar Sa Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques.
EP0840725A1 (en) 1995-07-01 1998-05-13 Smithkline Beecham Plc Azetidinone derivatives for the treatment of atherosclerosis
FR2743912B1 (fr) 1996-01-24 1998-04-10 Matra Communication Circuit de resolution d'equation-cle et decodeur reed-solomon incorporant un tel circuit
US5684794A (en) 1996-01-25 1997-11-04 Hazeltine Corporation Validation of subscriber signals in a cellular radio network
GB9608649D0 (en) 1996-04-26 1996-07-03 Smithkline Beecham Plc Novel compounds
CN1328277C (zh) * 1996-12-05 2007-07-25 安姆根有限公司 取代的嘧啶酮和吡啶酮化合物和它们的应用
GB9626615D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626536D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626616D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
EP1028955B1 (en) * 1997-11-06 2003-07-16 SmithKline Beecham plc Pyrimidinone compounds and pharmaceutical compositions containing them
ATE251613T1 (de) 1998-08-21 2003-10-15 Smithkline Beecham Plc Pyrimidinonderivate zur behandlung von atheroscleros
GB9910079D0 (en) 1999-05-01 1999-06-30 Smithkline Beecham Plc Novel compounds
AU766003B2 (en) 1999-05-01 2003-10-09 Smithkline Beecham Plc Pyrimidinone compounds
GB9910378D0 (en) 1999-05-05 1999-06-30 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
HUP0302480A3 (en) 2010-03-29
HU230767B1 (hu) 2018-03-28
ES2378059T3 (es) 2012-04-04
WO2002030904A1 (en) 2002-04-18
DK2258688T3 (da) 2013-02-04
EP1326841B1 (en) 2011-12-21
MXPA03003176A (es) 2003-07-14
EP1326841A1 (en) 2003-07-16
HK1058036A1 (en) 2004-04-30
CN1479724A (zh) 2004-03-03
KR100824134B1 (ko) 2008-04-21
HK1144941A1 (en) 2011-03-18
US20050014793A1 (en) 2005-01-20
IL155278A0 (en) 2003-11-23
JP2004512283A (ja) 2004-04-22
CN1951917B (zh) 2012-07-18
HUP0302480A2 (hu) 2003-12-29
NO20031626L (no) 2003-06-04
AR035349A1 (es) 2004-05-12
CY1113648T1 (el) 2016-06-22
PT2258688E (pt) 2013-02-04
US7235566B2 (en) 2007-06-26
GC0000307A (en) 2006-11-01
JP4212354B2 (ja) 2009-01-21
PL207560B1 (pl) 2011-01-31
CN1951917A (zh) 2007-04-25
IL155278A (en) 2015-05-31
NO325107B1 (no) 2008-02-04
ATE538096T1 (de) 2012-01-15
PT1326841E (pt) 2012-03-08
CZ304558B6 (cs) 2014-07-09
CA2425268C (en) 2011-09-13
MY135766A (en) 2008-06-30
SI1326841T1 (sl) 2012-04-30
EP2258688B1 (en) 2012-11-21
EP2258688A1 (en) 2010-12-08
PL366334A1 (en) 2005-01-24
DK1326841T3 (da) 2012-02-27
ES2399325T3 (es) 2013-03-27
SI2258688T1 (sl) 2013-03-29
AU2002210524B2 (en) 2004-06-03
NZ525225A (en) 2004-10-29
AU1052402A (en) 2002-04-22
GB0024808D0 (en) 2000-11-22
CZ20031009A3 (cs) 2003-11-12
BR0114576A (pt) 2004-07-27
BRPI0114576B1 (pt) 2017-05-30
CN1280275C (zh) 2006-10-18
KR20030036916A (ko) 2003-05-09
CY1112442T1 (el) 2015-12-09
US20040063753A1 (en) 2004-04-01
ZA200302785B (en) 2004-07-09
TWI293293B (en) 2008-02-11
CA2425268A1 (en) 2002-04-18

Similar Documents

Publication Publication Date Title
NO20031626L (no) Pyridonderivater for behandling av atherosklerose
NO20013369D0 (no) Arylpiperazinyl-cykloheksyl-indol-derivater for behandling av depresjon
NO20030012L (no) Fremgangsmåte for fremstilling av substituerte oktanoylamider
DK1343773T3 (da) Thiazolderivater til behandling af PPAR-beslægtede forstyrrelser
PT1343786E (pt) Novos derivados de pirazolopiridina substituidos por piridina
NO20013380L (no) 2-aminobenzoksazinonderivater for behandling av fedme
DE60223278D1 (de) Nicotin- oder isonicotin benzothiazole derivaten
NO20024775D0 (no) Hydroksyfenyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
DK1226131T3 (da) Isoxazolcarboxamidderivater
NO20020622D0 (no) Polymorfer av torsemid
NO20024776D0 (no) Hydroksyfenyl-piperazinyl-metyl-benzamidderivater til behandling av smerte
NO20024777D0 (no) Kinolinyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
DE60104791D1 (de) Cyclobutendion-Derivate zur Behandlung von Artherosclerose
NO20030699D0 (no) Fremgangsmåte for fremstilling av cilostazol
NO20030515L (no) Fremgangsmåte for fremstilling av dinapsolin
DK1294694T3 (da) Fremgangsmåde til fremstilling af quinolinderivater
NO20030717L (no) Forbindelser for behandling av avhengighetsforstyrrelser
NO20024887L (no) FremgangsmÕte for fremstilling av benzokondenserte heterosykliske forbindelser
NO20032297L (no) Fremgangsmåte for fremstilling av distamycinderivater
NO20023702D0 (no) Fremgangsmåte for fremstilling av 5-arylnikotinaldehyder
NO20020328D0 (no) Fremgangsmåte for fremstilling av 4-cyano-2-aminometyltiazol
NO20025385D0 (no) FremgangsmÕte for fremstilling av sulfonylbenzoylguanidiniumsalter
NO20020327D0 (no) Fremgangsmåte for fremstilling av 2-aminometyl-4-cyano-tiazol

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees